CPA
PCVX icon

Capital Performance Advisors’s Vaxcyte PCVX Stock Holding History

Capital Performance Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$343 – 1944
2024
Q3 		$343 Buy
+3
New +$270 ﹤0.01% 2416

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Performance Advisors's PCVX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 3 shares — an estimated $343 sold.

Capital Performance Advisors first reported a position in PCVX in Q3 2024 and held it in 1 quarter. The position peaked at $343 in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 3 Vaxcyte shares in Q4 2024, an estimated $343.
  • Capital Performance Advisors first reported a position in Vaxcyte in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Vaxcyte position peaked at $343 in Q3 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.